Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age

E D Moreira, A R Giuliano, J de Hoon, O-E Iversen, E A Joura, J Restrepo, P Van Damme, C Vandermeulen, M C Ellison, A Krick, C Shields, B Heiles, A Luxembourg, E D Moreira, A R Giuliano, J de Hoon, O-E Iversen, E A Joura, J Restrepo, P Van Damme, C Vandermeulen, M C Ellison, A Krick, C Shields, B Heiles, A Luxembourg

Abstract

A 9-valent HPV (9vHPV) vaccine has been developed to protect against HPV type 6/11/16/18/31/33/45/52/58-related infection and disease. Previous safety analyses from 7 clinical trials conducted in 9vHPV vaccine recipients 9-26 years of age, including comparisons of 9vHPV and quadrivalent HPV (qHPV) vaccines in girls and women 16-26 years of age, showed that the 9vHPV vaccine was generally well tolerated. Additional safety analyses were conducted to include the results of new clinical studies. The safety profile of the 9vHPV vaccine in prior qHPV vaccine recipients (n = 3756 from 1 randomized controlled trial and 2 open-label extension studies) and young men (n = 248 9vHPV and n = 248 qHPV vaccine recipients from 1 randomized controlled trial) was evaluated. Vaccine was administered as a 3-dose regimen (at Day 1 and Months 2 and 6), and adverse events (AEs) were monitored. The most common AEs were injection-site events (91.1% and 79.0% in prior qHPV vaccine recipients and young men, respectively), the majority of which were mild. Discontinuations due to an AE were rare (0.2% and 0.0% among prior qHPV vaccine recipients and young men, respectively). In young men, the AE profile of the 9vHPV vaccine was generally similar to that of the qHPV vaccine. Overall, the 9vHPV vaccine was generally well tolerated in prior qHPV vaccine recipients and in young men, with an AE profile generally consistent with that previously reported with the broader clinical program.

Trial registration: ClinicalTrials.gov NCT01047345 NCT00543543 NCT02114385.

Keywords: 9vHPV; cervical canJEL CODE.

Figures

Figure 1.
Figure 1.
Participant flow in prior qHPV vaccine recipients from Study 001-04 (A), Study 006 (B) and Study 006-02 (C) and among male participants from Study 020 (D) AE: adverse event.

References

    1. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR et al.. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–1056. doi:10.1016/S1470-2045(10)70230-8. PMID:20952254
    1. Pitisuttithum P, Velicer C, Luxembourg A. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. Expert Rev Vaccines. 2015;14(11):1405–1419. doi:10.1586/14760584.2015.1089174. PMID:26366475
    1. Alemany L, Saunier M, Alvarado-Cabrero I, Quirós B, Salmeron J, Shin HR, Pirog E, Guimerá N, Hernández-Suarez GA, Felix A et al.. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015;136(1):98–107. doi:10.1002/ijc.28963. PMID:24817381
    1. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura EA. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805–814. doi:10.1086/597071. PMID:19199546
    1. Joura EA, Ault A, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W et al.. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1997–2008. doi:10.1158/1055-9965.EPI-14-0410. PMID:25274978
    1. Serrano B, de Sanjosé S, Tous S, Quiros B, Muñoz N, Bosch X, Alemany L. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer. 2015;51(13):1732–1741. doi:10.1016/j.ejca.2015.06.001. PMID:26121913
    1. Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, et al.. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 Phase III clinical trials. Pediatrics. 2016;138(2):e20154387. doi:10.1542/peds.2015-4387. PMID:27422279
    1. Garland SM, Cheung TH, McNeill S, Petersen LK, Romaguera J, Vazquez-Narvaez J, Bautista O, Shields C, Vuocolo S, Luxembourg A. Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine. Vaccine. 2015;33(48):6855–6864. doi:10.1016/j.vaccine.2015.08.059. PMID:26411885
    1. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, et al.. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–723. doi:10.1056/NEJMoa1405044. PMID:25693011
    1. Guevara A, Cabello R, Woelber L, Moreira ED Jr, Joura E, Reich O, Shields C, Ellison MC, Joshi A, Luxembourg A. Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine. Vaccine. 2017;35:5050–5057. doi:10.1016/j.vaccine.2017.07.017. PMID:28789851
    1. Van Damme P, Meijer CJ, Kieninger D, Schuyleman A, Thomas S, Luxembourg A, Baudin M. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine. 2016;34(35):4205–4212. doi:10.1016/j.vaccine.2016.06.056. PMID:27354258
    1. Panagiotou OA, Befano BL, Gonzalez P, Rodriguez AC, Herrero R, Schiller JT, Kreimer AR, Schiffman M, Hildesheim A, Wilcox AJ et al.. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. BMJ. 2015;351:h4358. doi:10.1136/bmj.h4358. PMID:26346155
    1. Van Damme P, Bonanni P, Bosch FX, Joura E, Kjaer SK, Meijer CJ, Petry KU, Soubeyrand B, Verstraeten T, Stanley M. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines. Vaccine. 2016;34(6):757–761. doi:10.1016/j.vaccine.2015.12.063. PMID:26772631
    1. Centers for Disease Control and Prevention Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV. 2016. November 29 [accessed 2017March28] .
    1. Castellsague X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, Group T, Shields C, Liu K, Maansson R et al.. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33(48):6892–6901. doi:10.1016/j.vaccine.2015.06.088. PMID:26144901
    1. Audisio RA, Icardi G, Isidori AM, Liverani CA, Lombardi A, Mariani L, Mennini FS, Mitchell DA, Peracino A, Pecorelli S et al.. Public health value of universal HPV vaccination. Crit Rev Oncol Hematol. 2016;97:157–167. doi:10.1016/j.critrevonc.2015.07.015. PMID:26346895
    1. Lehtinen M, Apter D. Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination. Curr Opin Obstet Gynecol. 2015;27(5):326–332. doi:10.1097/GCO.0000000000000208. PMID:26308204
    1. Schmeler KM, Sturgis EM. Expanding the benefits of HPV vaccination to boys and men. Lancet. 2016;387(10030):1798–1799. doi:10.1016/S0140-6736(16)30314-2. PMID:27203488
    1. Stanley M. HPV vaccination in boys and men. Hum Vaccin Immunother. 2014;10(7):2109–2111. doi:10.4161/hv.29137. PMID:25424825
    1. Iversen OE, Miranda MJ, Ulied A, Soerdal T, Lazarus E, Chokephaibulkit K, Block SL, Skrivanek A, Nur Azurah AG, Fong SM et al.. Immunogenicity of the 9-valent HPV vaccine using 2-Dose regimens in girls and boys vs a 3-Dose Regimen in women. JAMA. 2016;316(22):2411–2421. doi:10.1001/jama.2016.17615. PMID:27893068
    1. Iwata S, Murata S, Han S, Wakana A, Sawata M, Tanaka Y. Safety and immunogenicity study of a 9-valent human papillomavirus vaccine administered to 9- to 15-year old Japanese Girls. Jpn J Infect Dis. 2017;70:368–373. doi:10.7883/yoken.JJID.2016.299. PMID:28003597
    1. European Medicines Agency (EMA) Summary of the risk management plan (RMP) for Gardasil 9 (human papillomavirus 9-valent vaccine (recombinant, adsorbed)) - EMA/226536. 2015. [accessed 2017February16]. .
    1. United States Food and Drug Administration Approval Letter - Gardasil 9. 2014. December 10 [accessed 2017February16] .
    1. Dana A, Buchanan KM, Goss MA, Seminack MM, Shields KE, Korn S, Cunningham ML, Haupt RM. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol. 2009;114(6):1170–1178. doi:10.1097/AOG.0b013e3181c2a122. PMID:19935016
    1. Goss MA, Lievano F, Buchanan KM, Seminack MM, Cunningham ML, Dana A. Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. Vaccine. 2015;33(29):3422–3428. doi:10.1016/j.vaccine.2015.04.014. PMID:25869893
    1. Gee J, Weinbaum C, Sukumaran L, Markowitz LE. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Hum Vaccin Immunother. 2016;12(6):1406–1417. doi:10.1080/21645515.2016.1168952. PMID:27029786

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever